Cargando…

Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers

The objective of this study was to determine if ovarian cancer patients with a TP53 mutation grouped by location of the mutation within the p53 protein structure exhibit differential survival outcomes. Data from patients with high grade serous ovarian cancer (HGS OvCa) (N = 316) or breast cancer (Br...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seagle, Brandon-Luke L., Eng, Kevin H., Dandapani, Monica, Yeh, Judy Y., Odunsi, Kunle, Shahabi, Shohreh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621916/ https://www.ncbi.nlm.nih.gov/pubmed/26215675

Ejemplares similares

Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer
por: Seagle, Brandon-Luke L., et al.
Publicado: (2016)

Delayed and clinically isolated port site carcinosarcoma recurrence as an early indicator of disseminated disease
por: Dandapani, Monica, et al.
Publicado: (2015)

Metastatic Uterine Leiomyosarcoma Involving Bilateral Ovarian Stroma without Capsular Involvement Implies a Local Route of Hematogenous Dissemination
por: Dandapani, Monica, et al.
Publicado: (2015)

Association of increased primary breast tumor AGR2 with decreased disease-specific survival
por: Ann, Phoebe, et al.
Publicado: (2018)

Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma
por: Shilpi, Arunima, et al.
Publicado: (2019)

Transversus abdominis plane block with liposomal bupivacaine compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early endometrial cancer: a cost-effectiveness analysis
por: Seagle, Brandon-Luke L., et al.
Publicado: (2017)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer
por: Eng, Kevin H., et al.
Publicado: (2015)

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
por: Wang, Y, et al.
Publicado: (2004)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Mullerian adenosarcoma of the cervix: Report of two large tumors with sarcomatous overgrowth or heterologous elements
por: Seagle, Brandon-Luke L., et al.
Publicado: (2014)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Transmission of X-linked Ovarian Cancer: Characterization and Implications
por: Etter, John Lewis, et al.
Publicado: (2020)

Urine Protein/Creatinine Ratios during Labor: A Prospective Observational Study
por: Tanamai, Vaya W., et al.
Publicado: (2016)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells
por: Lorenzon, Ilaria, et al.
Publicado: (2019)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer
por: Daudi, Sayeema, et al.
Publicado: (2014)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)
por: Oturkar, Chetan C., et al.
Publicado: (2022)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer
por: Borcoman, Edith, et al.
Publicado: (2023)

TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data
por: Chen, Zhe, et al.
Publicado: (2016)

Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer
por: Tahara, Tomomitsu, et al.
Publicado: (2016)

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
por: Chin, M, et al.
Publicado: (2017)

Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
por: Shi, Muqi, et al.
Publicado: (2020)

Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma
por: Das, Sunetra, et al.
Publicado: (2021)

Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer
por: Zhou, Jie, et al.
Publicado: (2022)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Uterine Lavage Identifies Cancer Mutations and Increased TP53 Somatic Mutation Burden in Individuals with Ovarian Cancer
por: Ghezelayagh, Talayeh S., et al.
Publicado: (2022)

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
por: Kringen, Pedro, et al.
Publicado: (2005)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vvs5g7uck6jlkutiam9e8go4qm